Cancer Center

Medicine & Life Sciences

1. Neoplasms 100%
2. Breast Neoplasms 87%
3. Melanoma 62%
4. Prostatic Neoplasms 60%
5. Prostate 55%
6. Drug Therapy 50%
7. Survival 48%
8. Cyclophosphamide 48%
9. 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one 47%
10. Doxorubicin 47%
11. Therapeutics 44%
12. Non-Small Cell Lung Carcinoma 39%
13. Adenoma 38%
14. Carcinoma 37%
15. Cell Line 36%
16. Cisplatin 34%
17. Small Cell Lung Carcinoma 32%
18. In Vitro Techniques 30%
19. Pharmacokinetics 29%
20. Bone Marrow Transplantation 28%
21. Neoplasm Metastasis 27%
22. Pharmaceutical Preparations 27%
23. Skin 26%
24. Bone Marrow 26%
25. Etoposide 25%
26. Recurrence 24%
27. Prostate-Specific Antigen 24%
28. Leukemia 24%
29. Placebos 23%
30. Integrins 23%
31. Acute Myeloid Leukemia 22%
32. Lymphocytes 21%
33. Selenium 21%
34. Colorectal Neoplasms 21%
35. Serum 21%
36. Contrast Media 20%
37. Radiotherapy 19%
38. Progression-Free Survival 19%
39. Mitomycin 18%
40. Acquired Immunodeficiency Syndrome 18%
41. Genes 18%
42. Confidence Intervals 18%
43. Microbubbles 17%
44. Apoptosis 17%
45. Immunotherapy 17%
46. Proteins 17%
47. Bone and Bones 17%
48. Colonic Neoplasms 17%
49. Busulfan 17%
50. Matrix Metalloproteinase 7 16%
51. Clinical Trials 16%
52. Antibodies 16%
53. Paclitaxel 16%
54. Biopsy 16%
55. promatrilysin 16%
56. Chemoprevention 16%
57. Liver 16%
58. Liposomes 16%
59. Vincristine 16%
60. Kidney 16%
61. Multiple Myeloma 16%
62. Growth 16%
63. kalinin 15%
64. Cell Transplantation 15%
65. Tea 15%
66. Keratins 15%
67. Disease-Free Survival 15%
68. Transplants 15%
69. Combination Drug Therapy 15%
70. Prostatic Intraepithelial Neoplasia 14%
71. Sexual and Gender Minorities 14%
72. Interferons 14%
73. DNA 14%
74. Pancreatic Neoplasms 14%
75. Magnetic Resonance Imaging 14%
76. Interleukin-2 14%
77. Tamoxifen 14%
78. Adenocarcinoma 14%
79. Polyps 14%
80. Monoclonal Antibodies 14%
81. Autologous Transplantation 13%
82. Fluorouracil 13%
83. Denosumab 13%
84. Sarcoma 13%
85. Enzymes 13%
86. Injections 13%
87. T-Lymphocytes 12%
88. Dacarbazine 12%
89. Mutation 12%
90. Antigens 12%
91. Appointments and Schedules 12%
92. Carcinogenesis 12%
93. Ipilimumab 12%
94. Biomarkers 12%
95. Breast 12%
96. Vinorelbine 12%
97. Lymphoma 12%
98. Mycobacterium bovis 12%
99. perfluoropentane 12%
100. Phenotype 12%